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Abstract
Background: The purpose of this study was to evaluate the correlation between immediate responsiveness with
the short-acting β2-agonist salbutamol and effects of treatment with the ultra-long-acting β2-agonist indacaterol in
patients with chronic obstructive pulmonary disease (COPD).
Methods: The REVERBREZ study was a phase IV, multicentre, open-label study in which patients with moderate-
to-severe COPD received indacaterol 150 μg once-daily for 5 months. The primary endpoint was the correlation
between immediate response of forced expiratory volume in 1 s (FEV1) post-inhalation of salbutamol (400 μg) at
study entry and the change from baseline in trough FEV1 after 1 month of indacaterol. Secondary endpoints
included dyspnoea measured by the modified Medical Research Council (mMRC) grade and health-related quality
of life measured by the clinical COPD questionnaire (CCQ).
Results: Of the 602 patients enrolled from 177 centres in France, 543 patients received at least one indacaterol
dose, 512 patients completed 1 month of indacaterol treatment (primary endpoint), and 400 patients completed
5 months of treatment. At study entry, mean FEV1 values before and after salbutamol inhalation were 1.54 ± 0.
50 L and 1.65 ± 0.53 L, respectively. Based on the magnitude of an immediate response of FEV1 after salbutamol
inhalation at study entry, patients were classified into reversible (Rv, ≥12% and ≥200 mL from pre-salbutamol
value; n = 106) and non-reversible (NRv, <12% or <200 mL from pre-salbutamol value; n = 431) groups. After
1 month of indacaterol treatment, mean absolute and relative difference in trough FEV1 were 100 mL and 9%,
respectively. No significant correlation was found between the immediate FEV1 response to salbutamol at study
entry and change from baseline in trough FEV1 after 1 month of indacaterol treatment (correlation coefficient
= 0.056 [95% CI;−0.032, 0.144] for absolute response and 0.028 [95% CI;−0.06, 0.116] for relative response). At all
subsequent visits, mMRC and CCQ scores, and FEV1 improved from baseline with no significant difference
between the Rv and NRv groups.
Conclusions: Immediate FEV1 response to salbutamol did not predict the long-term benefits observed with
indacaterol treatment in patients with COPD. Patients considered reversible or non-reversible to salbutamol
showed comparable improvements in lung function, dyspnoea and health-related quality of life.
Trial registration: ClinicalTrials.gov: NCT01272362. Date: January 5, 2011
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Background
Chronic obstructive pulmonary disease (COPD) is charac-
terised by persistent airflow limitation that is usually pro-
gressive and can lead to dyspnoea and impaired quality of
life [1, 2]. The Global Initiative for Chronic Obstructive
Lung Diseases (GOLD) strategy recommends long-acting
bronchodilators for maintenance treatment in patients
with moderate-to-severe COPD, as they have been shown
to improve lung function, dyspnoea, quality of life
and exacerbation rate [2]. Among inhaled long-acting β2-
agonists (LABAs), salmeterol and formoterol are ad-
ministered twice-daily and provide bronchodilation for
approximately 12 h [3–6], while indacaterol (Onbrez®
Breezhaler®), an ultra-LABA, is administered once daily
and provides 24 h of sustained bronchodilation [1].
Bronchodilator reversibility testing, despite not being
mentioned in the current treatment recommendations [2],
is commonly used in daily clinical practice to predict the
usefulness of a bronchodilator treatment [2]. Although the
test is simple, it is difficult to interpret or rely on because
the response may vary depending on the day and time of
testing, severity of baseline lung-function impairment, and
the number of drugs given to perform the test [2]. Pub-
lished data further suggests that acute reversibility in
response to bronchodilators in patients with COPD
does not predict clinical outcomes [7, 8].
The present study evaluated the correlation between
the immediate forced expiratory volume in 1 s (FEV1)
response with a short-acting β2-agonist, salbutamol
400 μg (via a metered-dose inhaler), and the clinical and
lung function responses to treatment with indacaterol
150 μg once daily (via the Breezhaler® device) after 1–5
months in patients with moderate-to-severe COPD.
Methods
Study design and patients
This was a phase IV, multicentre, open-label study con-
ducted at 177 centres in France between December 2010
and May 2012. Men and women aged ≥40 years, with a
smoking history of ≥10 pack-years and with moderate to
severe COPD [9] as defined by a post-bronchodilator
FEV1 ≥ 30% and <80% of the predicted value and a post-
bronchodilator FEV1 to forced vital capacity (FVC) ratio
<0.70, were recruited in the study. Patients were ex-
cluded if they had a COPD exacerbation within 6 weeks
before entering the study, long-term oxygen therapy,
asthma, or any concomitant pulmonary disease. Enrolled
patients were evaluated at five study visits (Fig. 1). At
Visit 1 (study entry), any long-acting bronchodilator
treatments were discontinued. Patients who were using
inhaled corticosteroids at study entry were allowed to
continue using it throughout the study without modify-
ing the drug dose or regimen. The salbutamol reversibil-
ity test was performed during which FEV1 was measured
30 min after inhalation of four puffs of salbutamol
(100 μg each). Patients were then classified into the re-
versible (Rv) group, defined by a post-bronchodilator in-
crease in FEV1 ≥ 12% and ≥200 mL from pre-salbutamol
value, or non-reversible (NRv) group, as defined by a
post-bronchodilator change in FEV1 < 12% or <200 mL
from pre-salbutamol value [9–11]. Salbutamol was the
only bronchodilator allowed for use during the 2-week
washout period. From Visit 2 (baseline) to Visit 5 (at
5 months), indacaterol 150 μg was administered once
daily, preferably in the morning and spirometry was per-
formed before inhalation of indacaterol (for measuring
trough FEV1) at each visit. There was one protocol
amendment. During the trial, the committee recom-
mended that 1 month of treatment (till Visit 3) was too
short for optimum evaluation of health-related quality of
life. The protocol was therefore amended to extend the
study duration by 4 months consisting of Visit 4 and
Visit 5 (Fig. 1).
Outcomes
Variables were evaluated at each treatment visit (Visit 2
to Visit 5) and the difference from baseline (Visit 2) was
Fig. 1 Study flow chart. Data presented are n (%); *During the
washout period, patients received salbutamol as a rescue
medication; ** All patients received indacaterol
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calculated in both the Rv and NRv groups. The primary
endpoint of the study was the correlation between the
immediate reversibility of FEV1 30 min post-inhalation
of salbutamol 400 μg at Visit 1 and the change in
trough FEV1 after 1 month of indacaterol treatment
(between Visit 3 and Visit 2). Absolute FEV1 reversibil-
ity (expressed in litres) was defined as the difference
between FEV1 before and after salbutamol administra-
tion. Relative FEV1 reversibility (expressed as a percent-
age value) was calculated as (absolute reversibility/FEV1
before salbutamol administration) × 100. Secondary
endpoints included FEV1 change across the study (min-
imal clinically important difference [MCID] ≥ 100 mL
improvement), dyspnoea measured by the modified
Medical Research Council (mMRC) grade (MCID de-
crease of ≥1 point) [12], and health-related quality of
life (HRQoL) measured by the clinical COPD question-
naire (CCQ; MCID decrease of ≥0.4 point) [13]. Safety
assessments included recording and monitoring of all
adverse events (AEs) and serious adverse events (SAEs).
Statistical analysis
A total of 540 patients were necessary to provide at least
80% power to detect a coefficient of correlation between
the immediate reversibility at 30 min post-inhalation in
FEV1 with salbutamol 400 μg at Visit 1 and the variation
in trough FEV1 between Visit 3 and Visit 2 of 0.12. Esti-
mating that about 10% of the data would be incomplete,
600 patients were to be included in the study. The
intent-to-treat (ITT) population used for evaluation of
primary and secondary endpoints included all enrolled
patients in the study who received at least one dose of
indacaterol 150 μg and for whom at least one endpoint
assessment was available after treatment administration.
The safety population included all enrolled patients, who
received at least one dose of indacaterol 150 μg and for
whom at least one tolerability assessment was available
after treatment administration. Descriptive statistics
were used for all analyses. The 95% confidence intervals
(CI) were provided for main assessment criteria. Statis-
tical tests between the Rv and NRv groups (Chi-square
or Wilcoxon rank sum test, according to the variables)
were bilateral with a significant threshold of 0.05. How-
ever, as there was no comparison group in this study,
analyses were exploratory and descriptive and p-values
were provided only as an indication. All analyses were
carried out using SAS v8.2.
Results
Of the 602 patients enrolled, 543 patients received at
least one dose of indacaterol, 512 patients completed the
study for the primary efficacy endpoint (Visit 3) and 400
patients were followed-up for 5 months (Fig. 1). Of the
195 (32.4%) patients who discontinued the study, 59
patients discontinued between Visit 1 and Visit 2 and
did not receive indacaterol; and 136 patients discontin-
ued between Visit 2 and Visit 3. Additionally, 7 patients
completed the study at Visit 3 according to the protocol
before amendment. Reasons for study discontinuation
are listed in Fig. 1.
Clinical characteristics of the treated patients (n = 543)
are presented in Table 1. The mean age was 63 years,
and most patients were men (74%) and ex-smokers
(64%). The mean ± SD FEV1 values before and after sal-
butamol inhalation were 1.54 ± 0.50 L and 1.65 ± 0.53 L,
respectively. Of the 543 treated patients, 6 patients had
non-interpretable reversibility results. In patients with
interpretable reversibility results, 106 patients (20%, Rv
group) showed significant FEV1 reversibility with sal-
butamol, and 431 patients (80%, NRv group) showed
non-significant reversibility. Baseline demographics
and patient characteristics were comparable between
the Rv and NRv groups (Table 1) and there was no dif-
ference in the use of inhaled corticosteroids between
these groups.
In patients who received indacaterol, mean absolute
and relative improvements in FEV1 after 1 month of
indacaterol treatment (Visit 3-Visit 2) were 100 (±260)
mL and 9 (±19) %, respectively. No statistically signifi-
cant correlation was observed between the change in
trough FEV1 at 1 month and absolute or relative revers-
ibility with salbutamol at study entry (Fig. 2a and b). Im-
provements in trough FEV1 from baseline was observed
in both the Rv and NRv groups at all visits (Fig. 3a) with
no statistically significant difference between the groups
Table 1 Demographics and baseline characteristics of patients
who received at least one dose of indacaterol
Variables Total population Rv group NRv group
(N = 543)a (n = 106) (n = 431)
Age, years 62.7 (9.6) 60.8 (9.9) 63.2 (9.5)
Male, n (%) 404 (74.4) 80 (75.5) 319 (74.0)
Current smoker, n (%) 196 (36.1) 43 (40.6) 151 (35.0)
Number of pack years 40.3 (19.3) 42.2 (20.7) 39.8 (19.0)
Years with COPD 9 (7.4) 9.9 (8.2) 8.8 (7.1)
Post-bronchodilator FEV1 (L) 1.65 (0.53) 1.88 (0.51) 1.59 (0.52)
Post-bronchodilator FEV1
(L), % predicted
57.3 (14.12) 62.8 (12.24) 55.9 (14.23)
Post-bronchodilator FVC (L) 3.01 (0.82) 3.36 (0.84) 2.92 (0.80)
FEV1/FVC (%) (Visit 2) 53.5 (14.15) 53.3 (10.80) 53.4 (14.89)
mMRC score (Visit 2) 1.4 (0.84) 1.3 (0.85) 1.4 (0.84)
CCQ score (Visit 2) 2.0 (0.99) 1.9 (0.93) 2.0 (1.01)
a 6 patients had non interpretable reversibility data; Data are presented as
mean (SD) unless otherwise specified; CCQ, Clinical COPD Questionnaire;
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume
in 1 second; FVC, forced vital capacity; mMRC, medical Modified Research
Council; SD, standard deviation
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at any visit. The proportion of patients reaching MCID
(≥100 mL improvement) for FEV1 at each visit was com-
parable in both groups (Fig. 3b).
Dyspnoea as measured by mMRC (mean difference in
mMRC ranged from−0.3 to−0.2, data not shown) im-
proved in both the Rv and NRv groups at all visits, and
there were no statistically significant differences between
these groups at any visit. The percentage of patients with
a ΔmMRC ≥1 from baseline was comparable between
the Rv and NRv groups at all visits (Fig. 4a). CCQ scores
improved from baseline in both the Rv and NRv groups
at all visits with no statistically significant differences be-
tween the groups at any visit (data not shown). The per-
centage of patients reaching the MCID in terms of
ΔCCQ ≥ 0.4 (Fig. 4b) from baseline was not significantly
different between the two groups at any visit.
Of the 543 patients included in the safety analysis, 264
(48.6%) and 33 (6.1%) patients experienced at least one
AE and SAE, respectively. Fifty-two (10%) patients re-
ported at least one AEs that was suspected to be related to
the study medication: Rv, n = 15 (14.2%) vs. NRv, n = 37
(8.6%), p = 0.10. Among the AEs (i.e., with a fre-
quency > 2%) COPD exacerbations, bronchitis, and
rhinitis were not different between the Rv and NRv
subgroups (p > 0.40). Compared to the NRv group, pa-
tients in the Rv group experienced cough more frequently
(9.4% vs 4.6%; p = 0.02) and a trend towards more frequent
dyspnoea (8.5% vs 4.6%; p = 0.07). The incidence of SAEs
were low and comparable between the Rv and NRv groups:
Rv, n = 6 (5.7%) vs NRv, n = 27 (6.3%). Overall, four deaths
were reported in the study. Two of these deaths (one death
after a COPD exacerbation and one sudden death) were
assessed by an investigator as suspected to be related to
study treatment. The other two deaths (one sudden death
because of an unknown cause, and one suicide) were deter-
mined as not related to study treatment.
Fig. 2 Correlation between Δ trough FEV1 at 1 month (Visit 3-Visit 2) with indacaterol therapy and a absolute FEV1 reversibility and b relative FEV1
reversibility to salbutamol at Visit 1. CI, confidence interval; FEV1, forced expiratory volume in 1 s; V1, Visit 1; V2, Visit 2; V3, Visit 3
Fig. 3 a Mean change in trough FEV1 (ml) from baseline and b proportion of patients reaching MCID for FEV1 during treatment with indacaterol
in reversible (Rv) and non-reversible (NRv) groups. FEV1, forced expiratory volume in 1 s; MCID, minimal clinically important difference; NRv,
non-reversible groups; Rv, reversible groups
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Discussion
The present study showed no correlation between the
immediate FEV1 response with the short-acting β2-agon-
ist salbutamol and the change in trough FEV1 after 1-
month of treatment with indacaterol 150 μg in patients
with moderate-to-severe COPD. When patients were
subdivided into the Rv and NRv groups (based on re-
sponse to salbutamol at study entry), there was no sig-
nificant difference in the improvement in trough FEV1
after 1 month of treatment with indacaterol. Similarly,
no statistically significant difference was observed be-
tween the Rv and NRv groups over the 5 months of this
study. Although numerical improvements in mMRC and
CCQ scores from baseline occurred in both groups, no
clinically significant difference was observed between
the Rv and NRv groups at any visit. These results sug-
gest that salbutamol responsiveness does not predict
the long-term lung function or clinical responses to
indacaterol.
These findings are consistent with a previous study
with another LABA (formoterol) that also reported no
significant correlation between reversibility with salbu-
tamol and clinical efficacy after 1 month of treatment
in patients with stable COPD [7]. Similar results were
reported after treatment with a long-acting antimus-
carinic agent in the Understanding Potential Long-term
Improvements in Function with Tiotropium (UPLIFT)
trial, which demonstrated that acute bronchodilator
responsiveness at baseline did not predict long-term
clinical response to tiotropium after 4 years of treat-
ment [14]. Tashkin et al. showed that irrespective of the
presence of short term response to tiotropium on day
1, treatment with tiotropium over a 1-year period re-
sulted in significant improvement in FEV1 compared to
baseline in both the responsive and poorly responsive
groups, with significant but low correlation (r = 0.43) at
the end of the study [15]. Our data corroborates the previ-
ous findings by showing the absence of a relationship
between acute effects of salbutamol and long term effects
of indacaterol, confirming that acute bronchodilator re-
sponsiveness should not be used to predict the effects of
long-acting bronchodilators.
Results from the present study concur with the GOLD
strategy and the other discussed studies [7, 14, 15], ac-
knowledging that the magnitude of reversibility of airflow
limitation following inhaled short-acting bronchodilators
does not predict the response to long-term treatment with
bronchodilators [9]. Non-reversibility of airflow limitation
has been used as an inclusion criterion in many COPD
studies until recently, however analyses of results from
several large studies have concluded that reversibility in
COPD patients is a continuous variable. Further, results of
reversibility testing vary between tests, time of test, and
baseline values and thus should not be used to select pa-
tients in a clinical trial or for determining the treatment
[16]. It has been also been shown that bronchodilator
reversibility is not reproducible over time and does not
predict disease progression or mortality [7]. In addition,
the current thresholds for spirometric measurements
for reversibility are also debatable. Some authors argue
that these tests may produce false positive results when
the baseline FEV1 value is low, and that FEV1 measure-
ments are not always repeatable due to noise effects
that can be >100 mL [13, 14, 16–18]. However, others
have suggested a lower threshold than the fixed 12%
and 200 mL European Respiratory Society (ERS)/
American Thoracic Society (ATS) criteria, particularly
in patients with low baseline FEV1 [10]. Pellegrino et al.
suggested that any threshold for reversibility testing will
have pros and cons, since most proposed thresholds are
within the natural variability of FEV1 and may not be
applicable to all disease conditions [19]. Although, the
present findings are not in favour of recommending
spirometry use for predicting clinical response, there is
an ongoing debate around the use of spirometry to as-
sess bronchodilator response [9, 19, 20]. Till date, only
Fig. 4 Proportion of patients achieving (a) ≥1 point improvement in mMRC score and b ≥0.4 point improvement in CCQ scores during treatment
with indacaterol. CCQ, clinical COPD questionnaire; mMRC, modified Medical Research Council; NRv, non-reversible groups; Rv, reversible groups
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short-acting bronchodilators (e.g. salbutamol) are used
for immediate reversibility testing, and we cannot ex-
clude a significant relationship between FEV1 change
at first dose of indacaterol, due to its rapid onset of ac-
tion, and long term response, as demonstrated with
tiotropium [15].
In this study, indacaterol was well tolerated with only
6.1% of patients reporting at least one SAE. The safety
profile was consistent with previous indacaterol studies
with approximately 5% of patients experiencing cough.
Interestingly, cough was more prevalent in patients in
the Rv group compared with the non-Rv group. Al-
though these findings require confirmation, they suggest
that bronchial responsiveness may favour cough induced
by indacaterol. Of the four deaths reported in the study,
two (one death of unknown cause and one following COPD
exacerbation) were suspected to be related to the study
drug. Sudden deaths are not rare in patients with COPD,
and severe COPD exacerbations may be fatal [21, 22].
The strengths of the present study are that the re-
sponse to indacaterol was studied by measuring FEV1
and validated tools (mMRC scale and CCQ question-
naire) for measuring patient-related outcomes under
real-life conditions. We also recognise some limitations
to this approach. Although the mMRC scale is easy to
use and is widely recommended for evaluating dyspnoea
in COPD patients in daily practice [9], it has the major
disadvantage of being poorly responsive to therapeutic
interventions, including bronchodilators and rehabilita-
tion. This was also the case in the present study, despite
a significant proportion of responders, when assessed by
using the CCQ and MCID. CCQ appears more respon-
sive than the mMRC scale in this real-life study. A com-
prehensive symptom assessment is also recommended in
addition to measuring breathlessness, using either the
COPD assessment test (CAT) or CCQ [9], but the
knowledge regarding responsiveness of these short ques-
tionnaires to pharmacotherapy remains limited. Interest-
ingly, the percentage of responders for HRQoL in the
present real-life study was close to those in the active
treatment arms of placebo-controlled studies using the
reference St. George Respiratory Questionnaire (SGRQ)
[23] [24], confirming the validity of these findings in this
non-placebo-controlled trial. The goal of the present study
was to evaluate the effects of indacaterol in daily practice
in symptomatic patients with post-bronchodilator FEV1/
FVC < 0.70, the diagnostic criteria for COPD according to
the GOLD document. Because FEV1/FVC ratio usually
declines with age, some subjects with FEV1/FVC <0.7
have a FEV1/FVC above the lower limit of the age-related
predicted value (also called lower limit of normal, LLN)
and may not be affected by COPD [25]. Specifically-
designed studies with sufficient statistical power will be
necessary to examine the effect of bronchodilators on
symptoms in these latter patients. Finally, there were high
rates of study discontinuation, mostly due to violation of
inclusion criteria and withdrawal of patient consent. Such
findings are usual in phase IV studies and are unlikely to
affect our conclusions.
Conclusion
In patients with COPD treated with indacaterol for
5 months, immediate FEV1 reversibility with salbutamol
at baseline did not predict the sustained response to
indacaterol in terms of lung function, health-related
quality of life or dyspnoea.
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